Paul M Silva's most recent trade in Rapport Therapeutics Inc. was a trade of 10,925 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on June 17, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Rapport Therapeutics Inc | Paul M. Silva | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2025 | 10,925 | 10,925 | - | - | Stock Option (Right to Buy) | |
| Nurix Therapeutics Inc | Paul M. Silva | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 May 2025 | 25,000 | 25,000 | - | - | Director Stock Option (right to buy) | |
| Nurix Therapeutics Inc | Paul M. Silva | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 May 2024 | 25,000 | 25,000 | - | - | Director Stock Option (right to buy) | |
| Nurix Therapeutics Inc | Paul M. Silva | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 May 2023 | 25,000 | 25,000 | - | - | Director Stock Option (right to buy) | |
| Nurix Therapeutics Inc | Paul M. Silva | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 May 2022 | 17,500 | 17,500 | - | - | Director Stock Option (right to buy) | |
| Nurix Therapeutics Inc | Paul M. Silva | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Oct 2021 | 35,000 | 35,000 | - | - | Director Stock Option (right to buy) |